Sage Therapeutic Stock Today
| SAGE Stock | USD 12.98 0.27 2.04% |
Performance0 of 100
| Odds Of DistressLess than 10
|
Sage Therapeutic is trading at 12.98 as of the 8th of May 2024, a -2.04 percent down since the beginning of the trading day. The stock's lowest day price was 12.62. Sage Therapeutic has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Equity ratings for Sage Therapeutic are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 8th of April 2024 and ending today, the 8th of May 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 18th of July 2014 | Category Healthcare | Classification Health Care |
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. Sage Therapeutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 60.18 M outstanding shares of which 9.31 M shares are at this time shorted by private and institutional investors with about 11.22 trading days to cover. More on Sage Therapeutic
Moving together with Sage Stock
| 0.79 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
Moving against Sage Stock
| 0.85 | HCM | HUTCHMED DRC | PairCorr |
| 0.69 | LPCN | Lipocine Financial Report 9th of May 2024 | PairCorr |
| 0.68 | FLGC | Flora Growth Corp Financial Report 20th of May 2024 | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Sage Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Sage Therapeutic's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Sage Therapeutic or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO President | Barry Greene | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Biotechnology, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation Analysts covering Sage Therapeutic report their recommendations after researching Sage Therapeutic's financial statements, talking to executives and customers, or listening in on Sage Therapeutic's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Sage Therapeutic. The Sage consensus assessment is calculated by taking the average forecast from all of the analysts covering Sage Therapeutic. | |||||
Sage Therapeutic's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Sage Therapeutic's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Sage Therapeutic's financial leverage. It provides some insight into what part of Sage Therapeutic's total assets is financed by creditors.
| |||||
Sage Therapeutic (SAGE) is traded on NASDAQ Exchange in USA. It is located in 215 First Street, Cambridge, MA, United States, 02142 and employs 487 people. Sage Therapeutic is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 781.16 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Sage Therapeutic's market, we take the total number of its shares issued and multiply it by Sage Therapeutic's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Sage Therapeutic conducts business under Biotechnology sector and is part of Health Care industry. The entity has 60.18 M outstanding shares of which 9.31 M shares are at this time shorted by private and institutional investors with about 11.22 trading days to cover.
Sage Therapeutic currently holds about 1.51 B in cash with (540.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 25.47, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Sage Therapeutic Probability Of Bankruptcy
Ownership AllocationSage Therapeutic maintains a total of 60.18 Million outstanding shares. The majority of Sage Therapeutic outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Sage Therapeutic to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Sage Therapeutic. Please pay attention to any change in the institutional holdings of Sage Therapeutic as this could imply that something significant has changed or is about to change at the company. Also note that roughly three million six hundred ten thousand nine hundred twenty invesors are currently shorting Sage Therapeutic expressing very little confidence in its future performance.
Check Sage Ownership Details
Sage Stock Price Odds Analysis
What are Sage Therapeutic's target price odds to finish over the current price? Based on a normal probability distribution, the odds of Sage Therapeutic jumping above the current price in 90 days from now is more than 93.0%. The Sage Therapeutic probability density function shows the probability of Sage Therapeutic stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.9762. This usually implies as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Sage Therapeutic will likely underperform. Additionally, sage Therapeutic has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Sage Therapeutic to move above the current price in 90 days from now is more than 93.0 (This Sage Therapeutic probability density function shows the probability of Sage Stock to fall within a particular range of prices over 90 days) .
Sage Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Sage Therapeutic that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Sage Therapeutic's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Sage Therapeutic's value.| Instituion | Recorded On | Shares | |
| Palo Alto Investors, Llc | 2023-12-31 | 991.5 K | |
| Dimensional Fund Advisors, Inc. | 2023-12-31 | 967.7 K | |
| Goldman Sachs Group Inc | 2023-12-31 | 953 K | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 870.6 K | |
| Samlyn Capital, Llc | 2023-12-31 | 768.9 K | |
| Northern Trust Corp | 2023-12-31 | 542.7 K | |
| Alyeska Investment Group, L.p. | 2023-09-30 | 528.8 K | |
| T. Rowe Price Associates, Inc. | 2023-12-31 | 478.1 K | |
| Fisher Asset Management, Llc | 2023-12-31 | 431.9 K | |
| Wellington Management Company Llp | 2023-12-31 | 6.1 M | |
| Fmr Inc | 2023-12-31 | 5.5 M |
Sage Therapeutic Historical Income Statement
Sage Therapeutic Income Statement is one of the three primary financial statements used for reporting Sage's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Sage Therapeutic revenue and expense. Sage Therapeutic Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, Sage Therapeutic's Total Revenue is projected to increase significantly based on the last few years of reporting. The current year's Gross Profit is expected to grow to about 107.4 M, whereas Selling General Administrative is forecasted to decline to about 144.2 M. View More FundamentalsSage Stock Against Markets
Picking the right benchmark for Sage Therapeutic stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Sage Therapeutic stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Sage Therapeutic is critical whether you are bullish or bearish towards Sage Therapeutic at a given time. Please also check how Sage Therapeutic's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Sage Therapeutic without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Anywhere Now
Portfolio AnywhereTrack or share privately all of your investments from the convenience of any device |
| All Next | Launch Module |
Sage Therapeutic Corporate Management
Elected by the shareholders, the Sage Therapeutic's board of directors comprises two types of representatives: Sage Therapeutic inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sage. The board's role is to monitor Sage Therapeutic's management team and ensure that shareholders' interests are well served. Sage Therapeutic's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sage Therapeutic's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anne Esq | General VP | Profile | |
| Jim Doherty | Chief Officer | Profile | |
| Christopher Benecchi | Chief Officer | Profile | |
| Laura MD | Chief Officer | Profile | |
| Albert Robichaud | Chief Scientific Officer | Profile |
How to buy Sage Stock?
Before investing in Sage Therapeutic, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Sage Therapeutic. To buy Sage Therapeutic stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Sage Therapeutic. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Sage Therapeutic stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Sage Therapeutic stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Sage Therapeutic stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Sage Therapeutic, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Sage Stock please use our How to Invest in Sage Therapeutic guide.
Already Invested in Sage Therapeutic?
The danger of trading Sage Therapeutic is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Sage Therapeutic is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Sage Therapeutic. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Sage Therapeutic is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Sage Therapeutic is a strong investment it is important to analyze Sage Therapeutic's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Sage Therapeutic's future performance. For an informed investment choice regarding Sage Stock, refer to the following important reports: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sage Therapeutic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.Note that the Sage Therapeutic information on this page should be used as a complementary analysis to other Sage Therapeutic's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Complementary Tools for Sage Stock analysis
When running Sage Therapeutic's price analysis, check to measure Sage Therapeutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sage Therapeutic is operating at the current time. Most of Sage Therapeutic's value examination focuses on studying past and present price action to predict the probability of Sage Therapeutic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sage Therapeutic's price. Additionally, you may evaluate how the addition of Sage Therapeutic to your portfolios can decrease your overall portfolio volatility.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |
Is Sage Therapeutic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sage Therapeutic. If investors know Sage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sage Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.39) | Revenue Per Share 1.519 | Quarterly Revenue Growth 1.399 | Return On Assets (0.32) | Return On Equity (0.55) |
The market value of Sage Therapeutic is measured differently than its book value, which is the value of Sage that is recorded on the company's balance sheet. Investors also form their own opinion of Sage Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Sage Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sage Therapeutic's market value can be influenced by many factors that don't directly affect Sage Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sage Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sage Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sage Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.